Annual report pursuant to Section 13 and 15(d)

Note 2 - Acquisitions (Tables)

Note 2 - Acquisitions (Tables)

12 Months Ended

Jun. 30, 2017

Notes Tables

Business Acquisition, Pro Forma Information [Table Text Block]

		Year Ended
		June 30,
		2017				2016
Net sales		$	564,220			$	523,840
Net income			99,380				110,536

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

		Zephyrus				Cliniqa				CyVek				Protein Simple				Novus

Current assets		$	56			$	11,926			$	1,206			$	19,660			$	10,739
Equipment			32				1,436				971				1,983				1,266
Other long-term assets			-				58				19				554				40
Intangible Assets:
Developed technology			8,300				18,000				20,200				39,200				5,010
Trade name			-				1,100				100				36,100				5,300
Customer relationships			-				27,000				600				101,600				14,400
Non-compete agreements			-				-				-				200				-
Goodwill			8,686				42,669				91,658				134,074				28,408
Total assets acquired			17,074				102,189				114,754				333,371				65,163

Liabilities			54				1,508				1,965				11,644				2,166
Deferred income taxes, net			2,521				17,793				(438	)			21,674				2,875
Net assets			14,500				82,888				113,227				300,053				60,122
Less fair-value of previous investment			-				-				18,300				-				-
Net assets acquired		$	14,500			$	82,888			$	94,927			$	300,053			$	60,122

Cash paid, net of cash acquired		$	8,000			$	82,888			$	59,927			$	300,053			$	60,122
Note Payable			-				-				-				-				-
Contingent consideration payable			6,500				-				35,000				-				-
Net purchase price		$	14,500			$	82,888			$	94,927			$	300,053			$	60,122

Space [Member]

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

		Final Opening Balance Sheet Allocation
Current assets, net of cash		$	2,128
Equipment			159
Intangible assets:
Customer relationships			6,769
Goodwill			3,517
Total assets acquired			12,573
Liabilities			1,444
Deferred income taxes, net			2,125
Net assets acquired		$	9,003

Cash paid, net of cash acquired		$	6,747
Consideration payable			2,256
Net purchase price		$	9,003

Advanced Cell Diagnostics (ACD) [Member]

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

		Preliminary Allocation at Acquisition Date				Adjustments to F air Value				Updated Opening Balance Sheet Allocation at June 30, 2017
Current assets, net of cash		$	25,196			$	(9,372	)		$	15,824
Equipment			2,757								2,757
Other long-term assets			3,812								3,812
Intangible assets:
Developed technology			107,000				43,000				150,000
Trade name			17,000				4,900				21,900
Customer relationships			77,000				(70,700	)			6,300
Non-compete agreement			200				(200	)			-
Goodwill			133,780				10,187				143,967
Total assets acquired			366,745				(22,185	)			344,560
Liabilities			3,591				588				4,179
Deferred income taxes, net			78,761				(26,018	)			52,743
Net assets acquired		$	284,393				3,245			$	287,638

Cash paid, net of cash acquired		$	246,193				845			$	247,038
Consideration payable			-				3,600				3,600
Fair value contingent consideration			38,200				(1,200	)			37,000
Net purchase price		$	284,393				3,245			$	287,638